A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad®
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CLARIFY MS
- Sponsors Merck KGaA
- 05 Jul 2018 Status changed from not yet recruiting to recruiting.
- 11 Jun 2018 Planned initiation date changed from 25 Apr 2018 to 15 Jun 2018.
- 24 Apr 2018 Planned End Date changed from 30 Dec 2021 to 25 Nov 2021.